Try your hand at this first in a series of questions on combination drug therapy to optimize treatment of T2DM.
We have created a series of questions on combination drug therapy to optimize treatment of T2DM. This first round is on concomitant use of the sodium-glucose contransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors.
SGLT2 inhibitors reduce hyperglycemia by preventing glucose reabsorption by the renal tubule and thus producing glucosuria. The DPP-4 inhibitors block the degradation of the gut hormone GLP-1 which stimulates release of insulin in a glucose-dependent manner and decreases circulating glucagon levels. When these mechanisms are combined, studies find, they are complementary and effective in reducing A1c in patients with type 2 diabetes (T2DM).
Question 1. Randomized controlled trials of combination therapy with an SGLT2 inhibitor and a DPP-4 inhibitor have shown that: